Albany Molecular Research Company Profile (NASDAQ:AMRI)

About Albany Molecular Research

Albany Molecular Research logoAlbany Molecular Research, Inc. is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM). The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing. API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized injectable formulations. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AMRI
  • CUSIP:
Key Metrics:
  • Previous Close: $16.28
  • 50 Day Moving Average: $15.11
  • 200 Day Moving Average: $14.67
  • 52-Week Range: $12.45 - $20.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 12.23
  • P/E Growth: 1.33
  • Market Cap: $574.22M
  • Outstanding Shares: 34,529,000
  • Beta: 1.4
Profitability:
  • Net Margins: -7.37%
  • Return on Equity: 3.17%
  • Return on Assets: 1.07%
Debt:
  • Debt-to-Equity Ratio: 1.41%
  • Current Ratio: 2.50%
  • Quick Ratio: 1.59%
Additional Links:
Companies Related to Albany Molecular Research:

Analyst Ratings

Consensus Ratings for Albany Molecular Research (NASDAQ:AMRI) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.00 (27.20% upside)

Analysts' Ratings History for Albany Molecular Research (NASDAQ:AMRI)
Show:
DateFirmActionRatingPrice TargetDetails
8/5/2016Morgan StanleyReiterated RatingBuy$17.00View Rating Details
10/26/2015First AnalysisUpgradeEqual Weight -> Overweight$25.00View Rating Details
11/6/2014JPMorgan Chase & Co.Reiterated RatingOverweight$25.00 -> $22.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Albany Molecular Research (NASDAQ:AMRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q216$0.32$0.36$123.10 million$116.50 millionViewListenView Earnings Details
5/10/2016Q1$0.21$0.07$107.20 million$102.80 millionViewListenView Earnings Details
2/17/2016Q415$0.36$0.40$133.40 million$126.40 millionViewListenView Earnings Details
11/5/2015Q315$0.11$0.11$95.15 million$101.40 millionViewListenView Earnings Details
8/4/2015Q215$0.18$0.22$85.00 million$85.20 millionViewListenView Earnings Details
5/5/2015Q115$0.15$0.20$81.50 million$75.10 millionViewN/AView Earnings Details
2/12/2015Q414$0.33$0.28$91.90 million$86.60 millionViewN/AView Earnings Details
11/5/2014$0.16($0.02)ViewN/AView Earnings Details
8/5/2014Q214$0.20$0.22$65.64 million$68.20 millionViewN/AView Earnings Details
5/6/2014Q114$0.23$0.16$62.19 million$51.00 millionViewN/AView Earnings Details
2/12/2014Q4$0.17$0.22ViewN/AView Earnings Details
11/6/2013Q313$0.11$0.13$62.10 million$53.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.12$50.00 million$59.30 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.10$0.23$53.70 million$59.40 millionViewN/AView Earnings Details
2/12/2013Q4 2012$0.09$0.17$56.49 million$59.10 millionViewN/AView Earnings Details
8/1/2012$0.02$0.01ViewN/AView Earnings Details
5/9/2012$0.05$0.02ViewN/AView Earnings Details
2/7/2012($0.12)($0.19)ViewN/AView Earnings Details
11/8/2011($0.05)($0.19)ViewN/AView Earnings Details
8/8/2011($0.03)($0.02)ViewN/AView Earnings Details
5/4/2011($0.14)($0.02)ViewN/AView Earnings Details
2/7/2011($0.15)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Albany Molecular Research (NASDAQ:AMRI)
Current Year EPS Consensus Estimate: $0.98 EPS
Next Year EPS Consensus Estimate: $1.35 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161$0.33$0.33$0.33
Q3 20161$0.13$0.13$0.13
Q4 20161$0.52$0.52$0.52
Q1 20171$0.20$0.20$0.20
Q2 20171$0.34$0.34$0.34
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Albany Molecular Research (NASDAQ:AMRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Albany Molecular Research (NASDAQ:AMRI)
Insider Ownership Percentage: 17.50%
Institutional Ownership Percentage: 71.39%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Steven R HagenSVPSell1,401$15.29$21,421.29View SEC Filing  
5/31/2016Kevin OconnorDirectorSell5,000$14.41$72,050.00View SEC Filing  
5/16/2016William S MarthCEOBuy12,500$12.86$160,750.00View SEC Filing  
5/13/2016George SvokosCOOBuy12,500$12.82$160,250.00View SEC Filing  
5/13/2016Steven R HagenSVPSell2,361$12.77$30,149.97View SEC Filing  
11/9/2015Ambra Constance M DMajor ShareholderSell50,000$19.60$980,000.00View SEC Filing  
8/17/2015Steven R HagenSVPSell1,000$20.45$20,450.00View SEC Filing  
6/10/2015Ambra Constance M DMajor ShareholderSell20,000$19.77$395,400.00View SEC Filing  
6/8/2015Steven R HagenSVPSell5,000$19.99$99,950.00View SEC Filing  
6/4/2015William S MarthCEOBuy10,000$19.98$199,800.00View SEC Filing  
6/1/2015Stuart M CableMajor ShareholderSell30,000$19.69$590,700.00View SEC Filing  
5/11/2015Ambra Constance M DMajor ShareholderSell20,000$19.11$382,200.00View SEC Filing  
5/8/2015Steven R HagenSVPSell14,500$19.27$279,415.00View SEC Filing  
4/10/2015Ambra Constance M DMajor ShareholderSell20,000$18.50$370,000.00View SEC Filing  
3/17/2015Steven R HagenSVPSell3,500$18.53$64,855.00View SEC Filing  
3/12/2015Kevin OconnorDirectorSell5,000$18.22$91,100.00View SEC Filing  
3/10/2015Ambra Thomas E Phd DDirectorSell20,000$17.65$353,000.00View SEC Filing  
3/10/2015George SvokosInsiderBuy10,000$17.72$177,200.00View SEC Filing  
3/5/2015William S MarthCEOBuy20,000$17.70$354,000.00View SEC Filing  
3/2/2015Stuart M CableMajor ShareholderSell30,000$16.39$491,700.00View SEC Filing  
2/10/2015Ambra Thomas E Phd DDirectorSell20,000$16.91$338,200.00View SEC Filing  
2/2/2015Stuart M CableMajor ShareholderSell30,000$16.32$489,600.00View SEC Filing  
1/12/2015Ambra Thomas E Phd DDirectorSell20,000$16.45$329,000.00View SEC Filing  
1/7/2015Stuart M CableMajor ShareholderSell7,694$16.00$123,104.00View SEC Filing  
1/5/2015Stuart M CableMajor ShareholderSell22,306$16.21$361,580.26View SEC Filing  
12/10/2014Ambra Constance M DMajor ShareholderSell20,000$16.24$324,800.00View SEC Filing  
12/5/2014Stuart M CableMajor ShareholderSell13,307$16.00$212,912.00View SEC Filing  
12/4/2014Stuart M CableMajor ShareholderSell16,693$16.00$267,088.00View SEC Filing  
11/10/2014William S MarthCEOBuy30,000$17.01$510,300.00View SEC Filing  
10/10/2014Ambra Constance M DMajor ShareholderSell20,000$21.62$432,400.00View SEC Filing  
10/1/2014Lori M HendersonSVPSell1,000$21.48$21,480.00View SEC Filing  
10/1/2014Stuart M CableMajor ShareholderSell30,000$21.61$648,300.00View SEC Filing  
9/10/2014Ambra Constance M DMajor ShareholderSell20,000$20.12$402,400.00View SEC Filing  
9/2/2014Lori M HendersonSVPSell2,500$19.56$48,900.00View SEC Filing  
8/28/2014Steven R HagenSVPSell1,250$19.74$24,675.00View SEC Filing  
8/14/2014Michael M NolanCFOSell10,000$19.76$197,600.00View SEC Filing  
8/12/2014Lori M HendersonSVPSell30,000$19.05$571,500.00View SEC Filing  
8/11/2014Ambra Thomas E Phd DDirectorSell20,000$18.99$379,800.00View SEC Filing  
8/8/2014Steven R HagenSVPSell10,797$18.99$205,035.03View SEC Filing  
8/1/2014Lori M HendersonSVPSell2,500$18.56$46,400.00View SEC Filing  
8/1/2014Stuart M CableMajor ShareholderSell30,000$18.69$560,700.00View SEC Filing  
7/10/2014Ambra Thomas E Phd DDirectorSell20,000$20.94$418,800.00View SEC Filing  
7/1/2014Lori M HendersonSVPSell2,500$20.62$51,550.00View SEC Filing  
7/1/2014Stuart M CableMajor ShareholderSell30,000$21.00$630,000.00View SEC Filing  
6/3/2014Steven R HagenSVPSell2,500$16.93$42,325.00View SEC Filing  
5/16/2014Steven HagenSVPSell1,250$15.45$19,312.50View SEC Filing  
5/15/2014George SvokosSVPBuy10,000$15.60$156,000.00View SEC Filing  
5/12/2014Steven HagenSVPSell5,897$15.00$88,455.00View SEC Filing  
5/12/2014William MarthCEOBuy30,000$15.40$462,000.00View SEC Filing  
5/1/2014Lori HendersonVPSell2,500$15.73$39,325.00View SEC Filing  
5/1/2014Stuart Cablemajor shareholderSell30,000$15.98$479,400.00View SEC Filing  
4/1/2014Lori HendersonVPSell2,500$18.74$46,850.00View SEC Filing  
4/1/2014Stuart Cablemajor shareholderSell30,000$18.52$555,600.00View SEC Filing  
2/27/2014Arthur RothDirectorSell5,000$15.95$79,750.00View SEC Filing  
2/27/2014Steven HagenSVPSell3,000$15.73$47,190.00View SEC Filing  
2/25/2014Steven HagenSVPSell2,500$15.19$37,975.00View SEC Filing  
2/24/2014Michael NolanCFOSell15,000$15.00$225,000.00View SEC Filing  
2/21/2014Steven HagenSVPSell1,500$14.87$22,305.00View SEC Filing  
2/19/2014Steven HagenSVPSell1,500$13.37$20,055.00View SEC Filing  
2/13/2014Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
12/4/2013Steven HagenSVPSell2,500$10.93$27,325.00View SEC Filing  
12/3/2013William MarthDirectorBuy30,000$10.75$322,500.00View SEC Filing  
11/22/2013Steven HagenSVPSell2,300$11.55$26,565.00View SEC Filing  
11/22/2013William MarthDirectorBuy20,000$11.57$231,400.00View SEC Filing  
9/13/2013Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
8/1/2013Stuart M CableMajor ShareholderSell30,000$12.53$375,900.00View SEC Filing  
7/1/2013Stuart M CableMajor ShareholderSell30,000$12.47$374,100.00View SEC Filing  
6/12/2013Stuart M CableMajor ShareholderSell30,000$12.00$360,000.00View SEC Filing  
5/22/2013Bruce J SargentSVPSell7,500$10.97$82,275.00View SEC Filing  
5/10/2013Steven R HagenSVPSell1,200$10.40$12,480.00View SEC Filing  
12/3/2012William S MarthDirectorBuy10,000$5.00$50,000.00View SEC Filing  
11/15/2012Ambra Thomas E Phd DCEOBuy10,000$3.80$38,000.00View SEC Filing  
8/9/2012Steven R HagenVPSell3,000$3.00$9,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Albany Molecular Research (NASDAQ:AMRI)
DateHeadline
openpr.com logoAlbany Molecular Research, Inc. (NASDAQ:AMRI) under Investigation for Long-Term Investors (NASDAQ:AMRI)
www.openpr.com - September 29 at 3:42 PM
biz.yahoo.com logoALBANY MOLECULAR RESEARCH INC Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Sta (NASDAQ:AMRI)
biz.yahoo.com - September 24 at 8:48 AM
capitalcube.com logoAlbany Molecular Research, Inc. – Value Analysis (NASDAQ:AMRI) : September 15, 2016 (NASDAQ:AMRI)
www.capitalcube.com - September 15 at 12:23 PM
capitalcube.com logoAlbany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : September 14, 2016 (NASDAQ:AMRI)
www.capitalcube.com - September 14 at 3:30 PM
News IconInvestor News: Investigation over possible Misconduct at Albany Molecular Research, Inc. (NASDAQ:AMRI) (NASDAQ:AMRI)
www.groundreport.com - September 13 at 8:20 AM
News IconScienter and Securities Law; Federal Tort Claims Act; Tax Prosecution (NASDAQ:AMRI)
www.newyorklawjournal.com - September 8 at 3:28 PM
4-traders.com logoInvestigation for Long-Term Investors in Albany Molecular Research, Inc. (NASDAQ:AMRI) Announced (NASDAQ:AMRI)
www.4-traders.com - August 30 at 11:29 AM
finance.yahoo.com logoAMRI CEO to Present at Morgan Stanley Global Healthcare Conference (NASDAQ:AMRI)
finance.yahoo.com - August 30 at 11:29 AM
reuters.com logoBRIEF-Albany Molecular Research announces restructuring plan of certain operations in U.S.and Europe (NASDAQ:AMRI)
www.reuters.com - August 29 at 9:08 PM
streetinsider.com logoAlbany Molecular Research (AMRI) Announces Euticals Acquisition-Related Restructuring Plan (NASDAQ:AMRI)
www.streetinsider.com - August 29 at 9:08 PM
biz.yahoo.com logoALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Material Impairm (NASDAQ:AMRI)
biz.yahoo.com - August 29 at 9:08 PM
News IconAlbany Molecular Research licenses CRISPR-Cas9 gene editing technology (NASDAQ:AMRI)
www.pharmabiz.com - August 27 at 8:18 AM
4-traders.com logoAlbany Molecular Research : AMRI CEO TO PRESENT AT BAIRD 2016 GLOBAL HEALTHCARE CONFERENCE (NASDAQ:AMRI)
www.4-traders.com - August 27 at 8:18 AM
capitalcube.com logoETF’s with exposure to Albany Molecular Research, Inc. : August 26, 2016 (NASDAQ:AMRI)
www.capitalcube.com - August 26 at 11:37 AM
4-traders.com logoAlbany Molecular Research : AMRI LICENSES CRISPR-CAS9 GENE EDITING TECHNOLOGY (NASDAQ:AMRI)
www.4-traders.com - August 25 at 3:31 PM
4-traders.com logoAlbany Molecular Research : Update in Lawsuit for Investors in Albany Molecular Research, Inc. shares announced by Shareholders Foundation (NASDAQ:AMRI)
www.4-traders.com - August 25 at 8:18 AM
capitalcube.com logoAlbany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : August 25, 2016 (NASDAQ:AMRI)
www.capitalcube.com - August 25 at 8:18 AM
News IconDrug Discovery Informatics Market size to exceed USD 6.5 billion by 2023 (NASDAQ:AMRI)
reports.pr-inside.com - August 24 at 3:31 PM
4-traders.com logoAMRI : CEO to Present at Baird 2016 Global Healthcare Conference (NASDAQ:AMRI)
www.4-traders.com - August 24 at 3:31 PM
finance.yahoo.com logoAMRI CEO to Present at Baird 2016 Global Healthcare Conference (NASDAQ:AMRI)
finance.yahoo.com - August 24 at 11:45 AM
4-traders.com logoAMRI : Licenses CRISPR-Cas9 Gene Editing Technology (NASDAQ:AMRI)
www.4-traders.com - August 23 at 8:46 PM
reuters.com logoBRIEF-Albany Molecular Research enters into non-exclusive commercial license agreement with broad institute of MIT and Harvard (NASDAQ:AMRI)
www.reuters.com - August 23 at 8:46 PM
finance.yahoo.com logoAMRI Licenses CRISPR-Cas9 Gene Editing Technology (NASDAQ:AMRI)
finance.yahoo.com - August 23 at 8:46 PM
finance.yahoo.com logo4:06 pm Albany Molecular enters into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology, financial terms were not disclosed (NASDAQ:AMRI)
finance.yahoo.com - August 23 at 8:46 PM
finance.yahoo.com logoUpdate in Lawsuit for Investors in Albany Molecular Research, Inc. shares announced by Shareholders Foundation (NASDAQ:AMRI)
finance.yahoo.com - August 23 at 3:30 PM
finance.yahoo.com logoUpdate in Lawsuit for Investors in Albany Molecular Research, Inc. shares announced by Shareholders Foundation (NASDAQ:AMRI)
finance.yahoo.com - August 23 at 3:30 PM
finance.yahoo.com logoRyan & Maniskas, LLP Announces Investigation of Albany Molecular Research Inc. (NASDAQ:AMRI)
finance.yahoo.com - August 10 at 9:56 PM
capitalcube.com logoAlbany Molecular Research, Inc. :AMRI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:AMRI)
www.capitalcube.com - August 10 at 3:50 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. (AMRI) (NASDAQ:AMRI)
finance.yahoo.com - August 9 at 12:15 PM
finance.yahoo.com logoRobbins Arroyo LLP Is Investigating the Officers and Directors of Albany Molecular Research, Inc. (AMRI) on Behalf of Shareholders (NASDAQ:AMRI)
finance.yahoo.com - August 8 at 3:32 PM
finance.yahoo.com logoEdited Transcript of AMRI earnings conference call or presentation 4-Aug-16 12:30pm GMT (NASDAQ:AMRI)
finance.yahoo.com - August 4 at 9:13 PM
biz.yahoo.com logoAlbany Molecular Research Inc Earnings Call (Q2 2016) (NASDAQ:AMRI)
biz.yahoo.com - August 4 at 3:33 PM
twst.com logoAMRI – Albany Molecular Research Inc.: AMRI Announces Second Quarter 2016 Results (NASDAQ:AMRI)
www.twst.com - August 4 at 3:33 PM
seekingalpha.com logoAlbany Molecular Research, Inc.'s (AMRI) CEO William Marth on Q2 2016 Results - Earnings Call Transcript (NASDAQ:AMRI)
seekingalpha.com - August 4 at 3:33 PM
finance.yahoo.com logoAlbany Molecular Research posts 2Q loss (NASDAQ:AMRI)
finance.yahoo.com - August 4 at 3:33 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Schubert Firm Announces Investigation into Possible Breaches of Fiduciary Duty by Albany Molecular Research Inc. Officers and Directors (NASDAQ:AMRI)
finance.yahoo.com - July 28 at 8:00 AM
capitalcube.com logoAlbany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : July 26, 2016 (NASDAQ:AMRI)
www.capitalcube.com - July 26 at 8:13 AM
capitalcube.com logoAlbany Molecular Research, Inc. – Value Analysis (NASDAQ:AMRI) : July 18, 2016 (NASDAQ:AMRI)
www.capitalcube.com - July 18 at 3:31 PM
prnewswire.com logoAMRI to Announce Second Quarter 2016 Results (NASDAQ:AMRI)
www.prnewswire.com - July 15 at 2:05 PM
biz.yahoo.com logoALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a D (NASDAQ:AMRI)
biz.yahoo.com - July 12 at 5:11 PM
capitalcube.com logoAlbany Molecular Research, Inc. breached its 50 day moving average in a Bullish Manner : AMRI-US : July 11, 2016 (NASDAQ:AMRI)
www.capitalcube.com - July 11 at 8:32 AM
publicnow.com logoAMRI Completes Acquisition of Euticals (NASDAQ:AMRI)
www.publicnow.com - July 11 at 7:43 AM
finance.yahoo.com logoTeewinot Life Sciences Corporation Licenses Biosynthetic Technology to AMRI for the Production and Sale of the First Commercially Available CBCA Analytical Standard (NASDAQ:AMRI)
finance.yahoo.com - June 22 at 8:00 AM
finance.yahoo.com logoAMRI Selected as a Dedicated Chemical Biology Consortium Center to Expand Drug Development (NASDAQ:AMRI)
finance.yahoo.com - June 14 at 8:05 AM
capitalcube.com logoAlbany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : June 13, 2016 (NASDAQ:AMRI)
www.capitalcube.com - June 13 at 8:17 AM
newsmaker.com.au logoDrug Discovery Informatics Market size is anticipated to reach around USD 6.5 billion by 2023 (NASDAQ:AMRI)
www.newsmaker.com.au - June 9 at 9:24 PM
biz.yahoo.com logoALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to (NASDAQ:AMRI)
biz.yahoo.com - June 3 at 4:32 PM
capitalcube.com logoAlbany Molecular Research, Inc. breached its 50 day moving average in a Bullish Manner : AMRI-US : June 2, 2016 (NASDAQ:AMRI)
www.capitalcube.com - June 2 at 8:05 AM
News IconAlbany Molecular Research, Inc. (AMRI) Given Buy Rating at Morgan Stanley - Let Me Know About This (NASDAQ:AMRI)
www.lmkat.com - May 30 at 12:28 PM
realistinvestor.com logoAlbany Molecular Research, Inc. (NASDAQ:AMRI) Current Deferred Tax Assets At $3.586 Millions - RealistInvestor.com (NASDAQ:AMRI)
www.realistinvestor.com - May 29 at 11:39 AM

Social

Albany Molecular Research (NASDAQ:AMRI) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff